Mantle Cell Lymphoma: Evidence‑Based Diagnosis and Management

Diagnosis

• A definitive diagnosis requires a lymph node, bone‑marrow, or involved‑tissue biopsy demonstrating cyclin D1 over‑expression and the t(11;14)(q13;q32) translocation by immunohistochemistry and molecular testing (FISH or PCR). 1
• Histology shows centrocytic morphology (small‑cell or blastoid variant) with cyclin D1 positivity in ≈ 98 % of cases. 1
• The Ki‑67 proliferation index is the most established biological risk factor and must be quantified with a standardized method. 1
• SOX11 negativity helps identify non‑nodal leukemic presentations that tend to follow a more indolent course. 2
• TP53 mutations confer an aggressive clinical course even when Ki‑67 is low and should be routinely assessed. 2

Staging and Baseline Work‑up

• Bone‑marrow biopsy and aspirate are mandatory because the majority of patients have marrow involvement. 1
• Upper and lower gastrointestinal endoscopy with multiple biopsies is recommended, as systematic evaluation reveals frequent GI involvement. 1
• Lumbar puncture is advised for high‑risk patients meeting ≥ 2 of: blastoid morphology, elevated LDH, poor performance status, or neurologic symptoms. 1
• Baseline labs should include a complete blood count, comprehensive chemistry (LDH, uric acid), and screening for HIV, hepatitis B and C. 1
• Imaging with contrast‑enhanced CT or PET‑CT per Lugano criteria is required; bulky disease is defined as a mass > 5 cm. 1

Prognostic Stratification

• Calculate the combined Mantle Cell Lymphoma International Prognostic Index (MIPI‑c), which incorporates age, ECOG performance status, leukocyte count, LDH level, and Ki‑67 index. 1

First‑Line Therapy

Limited Stage (I–II, non‑bulky)

• Short‑course conventional chemotherapy followed by consolidative radiotherapy (30–36 Gy) is the preferred approach. 2
• If a high tumor burden or adverse prognostic factors are present, systemic therapy identical to that used for advanced disease should be employed. 2

Advanced Stage (III–IV), Young & Transplant‑Eligible (< 65 years)

• Intensive induction regimens containing high‑dose cytarabine, followed by autologous stem‑cell transplantation (ASCT), provide superior response rates and overall survival (Level I, Grade B). 2
• A randomized trial showed that high‑dose cytarabine induction significantly prolongs median time to treatment failure (P = 0.038). 2
• Acceptable induction options include:
  
  • R‑CHOP alternating with R‑DHAP,
  • Nordic‑type protocols with high‑dose cytarabine,
  • R‑hyper‑CVAD alternating with high‑dose methotrexate/cytarabine (limited by toxicity). 2
• Regimens using high‑dose cytarabine alone are discouraged because they yield insufficient response rates. 2
• Consolidation with ASCT is recommended for eligible patients (Level I, Grade B). 2
• Total‑body irradiation adds benefit only for patients achieving a partial response; no advantage is seen in complete responders. 2
• Rituximab maintenance after R‑CHOP markedly improves progression‑free and overall survival (Level I, Grade A); meta‑analyses confirm this benefit across multiple studies. 2

Advanced Stage, Older or Unfit (≥ 65 years, transplant‑ineligible)

• Bendamustine‑rituximab (BR) is the established standard regimen. 1
• Monotherapy with rituximab alone or radio‑immunotherapy is not recommended because response rates are only moderate. 1
• R‑CHOP remains an alternative; however, BR provides superior progression‑free survival (35 months vs 21 months with R‑CHOP). 3
• VR‑CAP (bortezomib + rituximab + cyclophosphamide + doxorubicin + prednisone) yields PFS of 31 months versus 16 months with R‑CHOP. 3
• Rituximab maintenance after R‑CHOP improves PFS and overall survival (Level I, Grade A). 2

High‑Risk TP53‑Mutated Disease

• BTK‑inhibitor–based combinations are recommended because conventional chemotherapy and ASCT provide limited benefit. 4
• Ibrutinib combined with high‑dose cytarabine chemotherapy, and the regimen zanubrutinib + obinutuzumab + venetoclax, achieve approximately 96 % overall response and 88 % complete remission in this subgroup. 4

Indolent Non‑Nodal (Leukemic) Variant

• In patients with low tumor burden, bone‑marrow‑only disease, splenomegaly, SOX11 negativity, and Ki‑67 < 10 %, a brief period of watchful waiting under close surveillance is appropriate. 2
• No single biomarker reliably predicts an indolent course; however, concurrent TP53 mutations may still drive aggressive disease. 2

Relapsed / Refractory Disease

• Repeat biopsy at relapse is advised to reassess prognostic features. 3

Early Relapse (≤ 12–24 months)

• Use a non‑cross‑resistant regimen such as bendamustine‑based (e.g., R‑BAC) or high‑dose cytarabine‑based therapy after prior CHOP, or vice‑versa. 5
• Add rituximab if the previous antibody‑containing regimen achieved a remission lasting > 6 months. 5

Targeted Agents

• Ibrutinib provides the highest response rates and can produce durable remissions; it should be strongly considered in early relapse or refractory disease. 5
• Lenalidomide (preferably with rituximab) is an alternative when ibrutinib is contraindicated (e.g., high bleeding risk). 5
• Temsirolimus and bortezomib are effective, especially when combined with chemotherapy, based on phase II/III data. 5

Consolidation / Maintenance in Relapse

• Rituximab maintenance after salvage therapy prolongs PFS and overall survival (Level I, Grade A). 5
• Consolidative radio‑immunotherapy can extend remission duration, particularly in older patients unsuitable for dose‑intensified regimens. 5
• ASCT may be considered after relapse on conventional first‑line therapy, although the benefit is modest. 5
• A second autologous transplant has no demonstrated role in the relapsed setting. 5

Allogeneic Stem‑Cell Transplant

• Allogeneic transplantation is potentially curative and has achieved long‑term remissions even in early‑relapse or refractory mantle‑cell lymphoma (Level III, Grade B). 5
• Reduced‑intensity conditioning is appropriate given the typical older age of the patient population. 5

Supportive Care During Intensive Induction

• Granulocyte‑colony stimulating factor (G‑CSF) should be administered as needed for neutropenia. 4
• Red‑blood‑cell and platelet transfusions are indicated for symptomatic anemia or thrombocytopenia. 4
• Antimicrobial prophylaxis is recommended throughout periods of neutropenia. 4
• Close monitoring for tumor‑lysis syndrome is essential in patients with high tumor burden. 4

Response Assessment

• PET‑CT according to Lugano criteria may be used for response evaluation (optional). 5
• Imaging studies should be performed at mid‑treatment and at the end of therapy. 5
• Patients achieving less than a partial response should be considered for early salvage regimens. 5
• Minimal residual disease (MRD) status is an independent prognostic factor confirmed by multiple studies. 5

Pulmonary Involvement in Mantle Cell Lymphoma – Guideline Summary

Diagnostic Imaging and Staging

• Contrast‑enhanced CT of the chest or PET‑CT is required for staging and detecting pulmonary disease according to the International Lugano Classification for lymphoma. 6
• PET‑CT is also the imaging modality of choice for response assessment (mid‑treatment and end‑of‑therapy) using Lugano criteria. 7

Pre‑Transplant Evaluation

• Pulmonary function testing should be performed before autologous stem‑cell transplantation (ASCT) in transplant‑eligible patients as recommended by the Lugano staging framework. 8

Pathology and Biological Risk Assessment

• Ki‑67 proliferation index must be quantified with standardized methods because it is the most established biological risk factor for mantle‑cell lymphoma, per Lugano recommendations. 6

Systemic Treatment Strategy

• Management of pulmonary mantle‑cell lymphoma follows the same systemic therapy protocols as nodal disease; no lung‑specific treatment is recommended (Lugano guidance). 6

Role of Radiotherapy

• Consolidative external‑beam radiotherapy (30–36 Gy) may be considered for localized pulmonary involvement in limited‑stage (I–II) disease after short‑course chemotherapy, as per Lugano recommendations. 6
• Radiotherapy is not routinely employed for advanced‑stage pulmonary mantle‑cell lymphoma, where systemic therapy remains the priority. 6

Response Assessment

• PET‑CT performed according to Lugano criteria should be used to evaluate metabolic response at mid‑treatment and at the end of therapy. 7
• A complete metabolic response (Deauville score 1–3) is considered a complete remission even if residual pleural thickening or lung masses persist. 7

Prognostic Implications

• Pulmonary involvement alone does not independently affect prognosis; outcomes are driven by the MIPI‑c score, Ki‑67 index, TP53 mutation status, and blastoid morphology, as outlined in the Lugano classification. 6
• Patients presenting with pleural or endobronchial disease should be staged as advanced disease (stage III–IV) and managed accordingly under Lugano staging recommendations. [6] [8]